↓ Skip to main content

Dove Medical Press

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab

Overview of attention for article published in Journal of experimental pharmacology, May 2021
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#32 of 150)
  • Good Attention Score compared to outputs of the same age (68th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter
6 X users

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
12 Mendeley
Title
Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
Published in
Journal of experimental pharmacology, May 2021
DOI 10.2147/jep.s308388
Pubmed ID
Authors

Patricia Muñoz-Villegas, Alejandra Sanchez-Rios, Mayra G Quinonez-Alvarado, Oscar Olvera-Montaño, Juan D Quintana-Hau, Leopoldo Baiza-Duran

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 17%
Student > Bachelor 2 17%
Librarian 1 8%
Unspecified 1 8%
Other 1 8%
Other 0 0%
Unknown 5 42%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 2 17%
Biochemistry, Genetics and Molecular Biology 2 17%
Unspecified 1 8%
Social Sciences 1 8%
Medicine and Dentistry 1 8%
Other 1 8%
Unknown 4 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 December 2021.
All research outputs
#6,759,465
of 25,392,582 outputs
Outputs from Journal of experimental pharmacology
#32
of 150 outputs
Outputs of similar age
#140,562
of 453,943 outputs
Outputs of similar age from Journal of experimental pharmacology
#2
of 13 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 150 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 453,943 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.